Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma

References

• KaneRCBrossPFFarrellATVelcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapyOncologist20038650851314657528
   PubMed Web of Science ®Google Scholar
• KaneRCFarrellATSridharaRUnited States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapyClin Cancer Res2006121029556016707588
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myeloma. [see comment]New Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myeloma. [see comment]New Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWExtended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood2007110103557356017690257
   PubMed Web of Science ®Google Scholar
• AlbertsDSSalmonSEAdriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot studyCancer Chemother Rep197559(2 Pt 1):3453501097093
   PubMedGoogle Scholar
• AlexanianRBarlogieBTuckerSVAD-based regimens as primary treatment for multiple myelomaAm J Hematol199033286892301376
   PubMed Web of Science ®Google Scholar
• AndersonHScarffeJHRansonMVAD chemotherapy as remission induction for multiple myelomaBr J Cancer19957123263307841049
   PubMed Web of Science ®Google Scholar
• BarlogieBSmithLAlexanianREffective treatment of advanced multiple myeloma refractory to alkylating agentsN Engl J Med198431021135313566546971
   PubMed Web of Science ®Google Scholar
• CavoMZamagniETosiPSuperiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood20051061353915761019
   PubMed Web of Science ®Google Scholar
• SegerenCMSonneveldPvan der HoltBVincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myelomaBr J Haematol1999105112713010233375
   PubMed Web of Science ®Google Scholar
• RifkinRMGregorySAMohrbacherAPegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trialCancer2006106484885816404741
   PubMed Web of Science ®Google Scholar
• ZervasKDimopoulosMAHatzicharissiEPrimary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter studyAnn Oncol200415113413814679133
   PubMed Web of Science ®Google Scholar
• FerrazziEWoynarowskiJMArakaliADNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicinCancer Commun1991361731802049226
   PubMed Web of Science ®Google Scholar
• FoglesongPDReckordCSwinkSDoxorubicin inhibits human DNA topoisomerase ICancer Chemother Pharmacol19923021231251318169
   PubMed Web of Science ®Google Scholar
• FacchinettiTMantovaniACantoniLCantoniRSalmonaMIntercalation with DNA is a prerequisite for daunomycin, adriamycin and its congeners in inhibiting DNAase IChem Biol Interact197820197102630649
   PubMed Web of Science ®Google Scholar
• FornariFARandolphJKYalowichJCRitkeMKGewirtzDAInterference by doxorubicin with DNA unwinding in MCF-7 breast tumor cellsMol Pharmacol19944546496568183243
   PubMed Web of Science ®Google Scholar
• MomparlerRLKaronMSiegelSEAvilaFEffect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cellsCancer Res1976368289128951277199
   PubMed Web of Science ®Google Scholar
• EliotHGianniLMyersCOxidative destruction of DNA by the adriamycin-iron complexBiochemistry19842359289366324858
   PubMed Web of Science ®Google Scholar
• MyersCGianniLZweierJMuindiJSinhaBKEliotHRole of iron in adriamycin biochemistryFed Proc19864512279227973533644
   PubMedGoogle Scholar
• AdamsJPalombellaVJSausvilleEAProteasome inhibitors: a novel class of potent and effective antitumor agentsCancer Res199959112615262210363983
   PubMed Web of Science ®Google Scholar
• OrlowskiRZThe role of the ubiquitin-proteasome pathway in apoptosisCell Death Differ19996430331310381632
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDRichardsonPNF-kappaB as a therapeutic target in multiple myelomaJ Biol Chem200227719166391664711872748
   PubMed Web of Science ®Google Scholar
• HideshimaTMitsiadesCAkiyamaMMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood200310141530153412393500
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiVMolecular sequelae of proteasome inhibition in human multiple myeloma cellsProc Natl Acad Sci U S A20029922143741437912391322
   PubMed Web of Science ®Google Scholar
• RajkumarSVRichardsonPGHideshimaTProteasome inhibition as a novel therapeutic target in human cancerJ Clin Oncol200523363063915659509
   PubMed Web of Science ®Google Scholar
• AmbudkarSVKimchi-SarfatyCSaunaZP-glycoprotein: from genomics to mechanismOncogene200322477468748514576852
   PubMed Web of Science ®Google Scholar
• HideshimaTRichardsonPChauhanDThe proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cellsCancer Res20016173071307611306489
   PubMed Web of Science ®Google Scholar
• MaMHYangHHParkerKThe proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agentsClin Cancer Res2003931136114412631619
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSRichardsonPGThe proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood200310162377238012424198
   PubMed Web of Science ®Google Scholar
• OrlowskiRZBaldwinASJrNF-kappaB as a therapeutic target in cancerTrends Mol Med20028838538912127724
   PubMed Web of Science ®Google Scholar
• WangCYMayoMWBaldwinASJrTNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. [see comment]Science199627452887847878864119
   PubMed Web of Science ®Google Scholar
• FujitaTWashioKTakabatakeDProteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistanceInt J Cancer2005117467068215945097
   PubMed Web of Science ®Google Scholar
• SmallGWShiYYEdmundNAEvidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic roleMol Pharmacol20046661478149015448190
   PubMed Web of Science ®Google Scholar
• OrlowskiRZVoorheesPMGarciaRAPhase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood200510583058306515626743
   PubMed Web of Science ®Google Scholar
• BiehnSEMooreDTVoorheesPMExtended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicinAnn Hematol200786321121617146676
   PubMed Web of Science ®Google Scholar
• OrlowskiRZNaglerASonneveldPRandomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionJ Clin Oncol200725253892390117679727
   PubMed Web of Science ®Google Scholar
• NingYMNagherRSridharaRLiposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myelomaOncology (Williston Park)2007211215031508discussion 1511, 1513, 1516 passim.18077994
   PubMed Web of Science ®Google Scholar
• BladeJSamsonDReeceDCriteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantationBr J Haematol19981025111511239753033
   PubMed Web of Science ®Google Scholar
• BraccalentiGFerraraPGubbiottiMAntitumor activity of bortezomib-pegylated liposomal doxorubicine association as salvage therapy in multiple myeloma patientsBlood20071104832
   Web of Science ®Google Scholar
• San MiguelJHajekRNaglerADoxil + velcade in previously treated myeloma patients aged >65Haematologica2007976 Suppl 2159 abstract #620.
   Google Scholar
• HajekRNaglerASonneveldPDoxil + velcade in previously treated high risk myelomaHaematologica2007976 Suppl 2162 abstract #629.
   Google Scholar
• NaglerASonneveldPSpencerADoxil + velcade in previously treated myeloma patients with prior stem cell transplantHaematologica2007976 Suppl 2161 abstract #625.
   Google Scholar
• BladeJSan MiguelJNaglerAThe prolonged time to progression with pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposureBlood200711011410
   Web of Science ®Google Scholar
• SonneveldPHajekRNaglerACombined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/ lenalidomide therapyCancer2008112715291523718300257
   PubMed Web of Science ®Google Scholar
• SutherlandHJBladeJSan MiguelJEffect of disease stage and time since diagnosis on time to progression for pegylated liposomal doxorubicin + bortezomib vs bortezomib alone in relapsed or refractory multiple myelomaBlood2007110112740
   Web of Science ®Google Scholar
• KumarSBladeJSan MiguelJPegylated liposomal doxorubicin (PLD) in combination with bortezomib (B) may provide therapeutic advantage for high-risk multiple myeloma patients relapsing within 12 months of stem cell transplantBlood2007110112730
   Web of Science ®Google Scholar
• JakubowiakAJFriedmanJKendallTA phase II study of combination of bortezomib, liposomal doxorubicin, and dexamethasone (VDD) as first line therapy for multiple myelomaJ Clin Oncol2006 ASCO Annual Meeting Proceedings Part I20062418S17504
   Google Scholar
• OffidaniMBringhenSCorvattaLThalidomide-dexamethasone plus pegylated liposomal doxorubicin vs thalidomide-dexamethasone: a case-matched study in advanced multiple myelomaEur J Haematol200778429730217286608
   PubMed Web of Science ®Google Scholar
• DuryeaBGMHarousseauJLMiguelJSInternational uniform response criteria for multiple myelomaLeukemia20062091467147316855634
   PubMed Web of Science ®Google Scholar
• OffidaniMPolloniCCorvattaLThaDD-V treatment for patients with relapsed/refractory multiple myeloma: a feasibility/activity studyBlood2007110112729
   Web of Science ®Google Scholar
• Chanan-KhanAAPadmanabhanSMillerKCFinal results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refactory (ref) multiple myelomaBlood20061083539
   Web of Science ®Google Scholar
• ChariAKaplanLLinkerCPhase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myelomaBlood20051065182
   Web of Science ®Google Scholar
• RiesLAGMelbertDKrapchoMSEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, 2007.
   Google Scholar
• OrlowskiRZPetersonBLSanfordBBortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301Blood200610811797
   Web of Science ®Google Scholar